Key result
RRT in microaxial flow pump-supported cardiogenic shock is linked to ~48% higher 180-day mortality.
Why the study?
Microaxial flow pumps improve outcomes in myocardial infarction-related cardiogenic shock but increase the risk of acute kidney injury requiring renal replacement therapy (RRT). This study determined the incidence, associated factors, and mortality impact of RRT in a real-world cohort of miscellaneous cardiogenic shock patients supported with microaxial flow pumps.
Is renal replacement therapy associated with increased 180-day all-cause mortality in cardiogenic shock patients supported with microaxial flow pumps?
Cohort (n=972)
Yes
Is renal replacement therapy associated with increased 180-day all-cause mortality in cardiogenic shock patients supported with microaxial flow pumps?
Answers are grounded in this paper and cite their sources.
In cardiogenic shock patients supported by microaxial flow pumps, renal replacement therapy is required in over one-third of patients, is linked to markers of greater shock severity and obesity/renal dysfunction, and is independently associated with significantly higher 180-day mortality.
Microaxial flow pumps (mAFP) improve hemodynamics and outcomes in myocardial infarction-related cardiogenic shock (CS) but are associated with an increased risk of acute kidney injury (AKI) requiring renal replacement therapy (RRT). We aimed to determine the incidence and factors associated with RRT and evaluate its association with mortality in a real-world cohort of miscellaneous CS patients supported with mAFP. We conducted a retrospective multicentre registry including CS patients supported with mAFP across 11 European centres. The association between RRT and the primary outcome of 180-day all-cause mortality (with survival censored at heart transplantation or durable left ventricular assist device implantation) was assessed using a 1:1 propensity score-matched cohort. Factors associated with RRT were identified using multivariable logistic regression. Among 1043 patients, 972 were included, of whom 340 (35.0%) required RRT. RRT was associated with higher 180-day all-cause mortality both before (Kaplan-Meier estimates, 59.7% vs. 35.2%; HR 2.04, 95% CI 1.67-2.49; p < 0.01) and after propensity score matching (59.0% vs. 41.4%; HR 1.48, 95% CI 1.14-1.92; p < 0.01); restricted mean survival difference -25.5 days, 95% CI - 39.9 to -10.2. Factors associated with RRT included BMI ≥ 30 kg/m² (adjusted OR [aOR] 1.69; 95% CI 1.15-2.46), baseline serum creatinine (per 20 µmol/L increase: aOR 1.18; 95% CI 1.12-1.24), norepinephrine use (aOR 1.72; 95% CI 1.19-2.49), and lactate ≥4 mmol/L at implantation (aOR 1.56; 95% CI 1.11-2.20). In this large European registry of mAFP-supported CS, RRT was frequent and associated with increased 180-day mortality and greater shock severity.
No takes yet. Share an insight, caveat, or question.
Ughetto et al. (2026) conducted a cohort in Cardiogenic shock supported by microaxial flow pumps (n=972). Renal replacement therapy (RRT) vs. No renal replacement therapy was evaluated on 180-day all-cause mortality (censored at heart transplantation or durable left ventricular assist device implantation) (HR 1.48, 95% CI 1.14-1.92, p=<0.01). Renal replacement therapy in microaxial flow pump-supported cardiogenic shock was associated with higher 180-day mortality.
Synapse has enriched 10 related papers. Consider them for comparative context: